CRISPR Therapeutics AG (CRSP) Profit Margins posted 34.00% in the last twelve months: The key fundamentals to watch – Invest Chronicle
Home  »  News   »  CRISPR Therapeutics AG (CRSP) Profit Margins poste...

CRISPR Therapeutics AG (CRSP) Profit Margins posted 34.00% in the last twelve months: The key fundamentals to watch

At the end of the latest market close, CRISPR Therapeutics AG (CRSP) was valued at $70.00. In that particular session, Stock kicked-off at the price of $71.01 while reaching the peak value of $75.24 and lowest value recorded on the day was $59.82. The stock current value is $64.67.Recently in News on June 11, 2022, CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress. -70% overall response rate (ORR) and 30% complete response (CR) rate in peripheral T-cell lymphoma (PTCL) and cutaneous T cell lymphoma (CTCL) at Dose Level 3 (DL3) and above; clinical benefit for 90% of patients-. You can read further details here

CRISPR Therapeutics AG had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $79.40 on 01/03/22, with the lowest value was $42.51 for the same time period, recorded on 05/12/22.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


CRISPR Therapeutics AG (CRSP) full year performance was -50.11%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, CRISPR Therapeutics AG shares are logging -61.91% during the 52-week period from high price, and 52.13% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $42.51 and $169.76.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 7417972 for the day, which was evidently higher, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the CRISPR Therapeutics AG (CRSP) recorded performance in the market was -14.66%, having the revenues showcasing -1.51% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.63B, as it employees total of 473 workers.

CRISPR Therapeutics AG (CRSP) in the eye of market guru’s

During the last month, 17 analysts gave the CRISPR Therapeutics AG a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 8 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 1 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 59.49, with a change in the price was noted +2.83. In a similar fashion, CRISPR Therapeutics AG posted a movement of +4.58% for the period of last 100 days, recording 1,612,390 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for CRSP is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.

CRISPR Therapeutics AG (CRSP): Stocks Technical analysis and Trends

Raw Stochastic average of CRISPR Therapeutics AG in the period of last 50 days is set at 67.33%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 55.13%. In the last 20 days, the company’s Stochastic %K was 69.96% and its Stochastic %D was recorded 66.53%.

If we look into the earlier routines of CRISPR Therapeutics AG, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -14.66%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -21.83%, alongside a downfall of -50.11% for the period of the last 12 months. The shares increased approximately by 17.01% in the 7-day charts and went up by 14.48% in the period of the last 30 days. Common stock shares were lifted by -1.51% during last recorded quarter.

Leave a Comment

Your email address will not be published.

On Key

Related Posts